Immunoassays for Neurological Biomarkers Market Size, Share, and Trends, 2026-2033 | Blood-Based Diagnostics and Precision Medicine Fuel Growth to USD 2.12 Billion

Blood-based, high-sensitivity immunoassays are expanding early neurological diagnosis, clinical adoption, drug development, and precision medicine.

Dublin, Nov. 17, 2026 (GLOBE NEWSWIRE) -- "Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report by Product, Disease, Application, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

Global Immunoassay for Neurological Biomarkers Market to Reach USD 2.12 Billion by 2033

The global immunoassay for neurological biomarkers market was valued at an estimated USD 1.08 billion in 2025 and is projected to reach USD 2.12 billion by 2033. The market is expected to expand at a CAGR of 8.91% from 2026 to 2033, driven by the rising prevalence of neurodegenerative diseases, growing demand for early diagnosis, adoption of minimally invasive blood-based testing, and continued advances in high-sensitivity immunoassay technologies.

Increasing demand for earlier detection of neurological disorders is strengthening the clinical role of biomarker-based immunoassays. Conditions such as Alzheimer's disease frequently remain undiagnosed during their early stages, increasing the need for accessible and accurate diagnostic solutions that can support timely treatment decisions. In October 2025, F. Hoffmann-La Roche received U.S. FDA clearance for its Elecsys pTau181 blood-based immunoassay, which is designed to assist with the early detection of Alzheimer's disease in clinical and primary care settings. Such tests can improve patient referral pathways, reduce diagnostic delays, and support broader neurological biomarker testing across healthcare systems.

The shift toward minimally invasive blood-based diagnostics is also accelerating market adoption. Compared with cerebrospinal fluid testing and imaging techniques, blood-based immunoassays can improve patient compliance, reduce procedural risks, and support higher testing volumes. Their suitability for primary care practices and clinical laboratories is expanding access to neurological diagnostics beyond specialized care centers.

High-sensitivity digital immunoassays, including Simoa platforms, enable the detection of low-abundance biomarkers such as pTau217 and neurofilament light chain. These platforms are improving analytical sensitivity, reproducibility, diagnostic accuracy, and laboratory throughput. In May 2025, Fujirebio received U.S. FDA clearance for its Lumipulse G pTau217/?-Amyloid 1-42 plasma ratio test, a blood-based immunoassay developed to detect Alzheimer's pathology. Regulatory progress involving these technologies is expected to support large-scale clinical deployment and wider adoption.

Neurological biomarkers are also becoming increasingly important in drug development and precision medicine. Immunoassays support patient stratification, treatment monitoring, clinical trial enrollment, and endpoint evaluation. Development of disease-modifying therapies for Alzheimer's disease has intensified demand for accurate diagnostic tools that can identify eligible patients at early stages. As biomarker-driven treatment strategies advance, immunoassays are expected to play a growing role in personalized neurological care and therapeutic decision-making.

Report Scope and Segmentation

The report forecasts revenue growth at global, regional, and country levels and analyzes industry trends across market segments from 2021 to 2033. The market is segmented by product, disease, application, and region.

Product Outlook (Revenue, USD Million, 2021-2033)

  • Instruments
  • Reagents
  • Services

Disease Outlook (Revenue, USD Million, 2021-2033)

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others

Application Outlook (Revenue, USD Million, 2021-2033)

  • In Vitro Diagnostics Application
  • Research Application

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America: U.S., Canada, and Mexico
  • Europe: UK, Germany, France, Italy, Spain, Denmark, Sweden, and Norway
  • Asia-Pacific: Japan, China, India, Australia, South Korea, and Thailand
  • Latin America: Brazil and Argentina
  • Middle East & Africa: South Africa, Saudi Arabia, UAE, and Kuwait

Across these markets, continued regulatory approvals, investment in neurological research, expansion of clinical laboratory infrastructure, and demand for scalable testing are expected to shape industry growth through 2033.

Key Attributes:

Report Attribute Details
No. of Pages 150
Forecast Period 2025 - 2033
Estimated Market Value (USD) in 2025 $1.08 Billion
Forecasted Market Value (USD) by 2033 $2.12 Billion
Compound Annual Growth Rate 8.9%
Regions Covered Global


Key Topics Covered:

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Immunoassays for Neurological Biomarkers Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter's Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis

Chapter 4. Global Immunoassays for Neurological Biomarkers Market, by Product Business Analysis
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Instruments
4.4.1. Instruments Market, 2021 - 2033 (USD Million)
4.5. Reagents
4.5.1. Reagents Market, 2021 - 2033 (USD Million)
4.6. Services
4.6.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Immunoassays for Neurological Biomarkers Market: Segment Analysis, by Disease Business Analysis
5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
5.4. Alzheimer's Disease
5.4.1. Alzheimer's Disease Market, 2021 - 2033 (USD Million)
5.5. Parkinson's Disease
5.5.1. Parkinson's Disease Market, 2021 - 2033 (USD Million)
5.6. Multiple Sclerosis
5.6.1. Multiple Sclerosis Market, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Immunoassays for Neurological Biomarkers Market: Segment Analysis, by Application Business Analysis
6.1. Application Market Share, 2025 & 2033
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. In Vitro Diagnostics Application
6.4.1. In Vitro Diagnostics Application Market, 2021 - 2033 (USD Million)
6.5. Research Application
6.5.1. Research Application Market, 2021 - 2033 (USD Million)

Chapter 7. Immunoassays for Neurological Biomarkers Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
7.3.1. Standard Country Analysis
7.3.1.1. Key Country Dynamics
7.3.1.2. Target Disease Prevalence
7.3.1.3. Regulatory Framework
7.3.1.4. Reimbursement Framework
7.4. North America
7.4.1. North America Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
7.4.2. U.S. Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Canada Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. Mexico Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
7.5.1. Europe Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. UK Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Germany Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.4. France Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.5. Italy Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.6. Spain Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.7. Denmark Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.8. Sweden Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.9. Norway Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. Japan Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. China Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. India Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. Australia Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.6. South Korea Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.7. Thailand Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.2. Brazil Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.3. Argentina Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.2. South Africa Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.3. Saudi Arabia Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.4. UAE Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.5. Kuwait Immunoassays for Neurological Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Profile Coverage
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Qiagen
8.5.3. Abbott
8.5.4. Merck KGaA & Co., Inc.
8.5.5. Johnson & Johnson Services, Inc.
8.5.6. Thermo Fisher Scientific , Inc.
8.5.7. Bio-Rad Laboratories , Inc.
8.5.8. Sysmex Corporation
8.5.9. Merck KGaA KGaA.
8.5.10. F. Hoffmann-La Roche Ltd.
8.5.11. Nimble Therapeutics

List of Tables [97]

List of Figures [79]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/fklknv

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900